Synergy Pharmaceuticals Announces SP-333 Data Presentation at the 17th Neurogastroenterology & Motility Scientific Meeting

  Synergy Pharmaceuticals Announces SP-333 Data Presentation at the 17th
  Neurogastroenterology & Motility Scientific Meeting

Business Wire

NEW YORK -- September 17, 2013

Synergy Pharmaceuticals Inc. (Nasdaq: SGYP) today announced a poster
presentation on SP-333, its next-generation guanylate cyclase-C (GC-C) agonist
in development for the treatment of gastrointestinal (GI) conditions, will be
featured at the 17^th Neurogastroenterology & Motility Scientific Meeting
being held September 20-22, 2013 at the Hyatt Regency Resort & Spa in
Huntington Beach, California.

Poster: SP-333, a GC-C agonist, ameliorates GI inflammation via a cyclic GMP
mediated mechanism to downregulate IKK and NF-KappaB (106), authored by 
Kunwar Shailubhai, Ph.D., M.B.A.

Friday, September 20 (5:00pm-7:00pm) and Saturday, September 21

About Synergy Pharmaceuticals Inc.

Synergy Pharmaceuticals is a biopharmaceutical company focused on the
development of new drugs to treat patients with gastrointestinal (GI) diseases
and disorders. Synergy's lead proprietary drug candidate, plecanatide, is a
synthetic analog of the human GI hormone, uroguanylin, and functions by
activating the guanylate cyclase-C (GC-C) receptor on epithelial cells of the
GI tract. In early 2013, Synergy announced positive results from a large
multicenter trial of plecanatide in patients with chronic idiopathic
constipation (CIC) and recently completed an end-of-phase 2 meeting with the
U.S. Food and Drug Administration (FDA) covering the registration program for
plecanatide to treat CIC. Synergy is also developing plecanatide for the
treatment of irritable bowel syndrome with constipation (IBS-C), recently
announcing that it had reached the halfway mark for total enrollment in a
plecanatide phase 2b clinical trial in patients with IBS-C. Synergy’s second
GC-C agonist, SP-333, is in clinical development to treat inflammatory bowel
disease and other GI conditions and has recently completed its first phase I
trial in healthy volunteers. More information is available at

Forward-Looking Statements

Certain statements in this press release are forward-looking within the
meaning of the Private Securities Litigation Reform Act of 1995. These
statements may be identified by the use of forward- looking words such as
"anticipate," "planned," "believe," "forecast," "estimated," "expected," and
"intend," among others. These forward-looking statements are based on
Synergy's current expectations and actual results could differ materially.
There are a number of factors that could cause actual events to differ
materially from those indicated by such forward-looking statements. These
factors include, but are not limited to, substantial competition; our ability
to continue as a going concern; our need for additional financing;
uncertainties of patent protection and litigation; uncertainties of government
or third party payer reimbursement; limited sales and marketing efforts and
dependence upon third parties; and risks related to failure to obtain FDA
clearances or approvals and noncompliance with FDA regulations. As with any
pharmaceutical under development, there are significant risks in the
development, regulatory approval and commercialization of new products. There
are no guarantees that future clinical trials discussed in this press release
will be completed or successful or that any product will receive regulatory
approval for any indication or prove to be commercially successful. Investors
should read the risk factors set forth in Synergy's Form 10-K for the year
ended December 31, 2012 and other periodic reports filed with the Securities
and Exchange Commission. While the list of factors presented here is
considered representative, no such list should be considered to be a complete
statement of all potential risks and uncertainties. Unlisted factors may
present significant additional obstacles to the realization of forward-looking
statements. Forward-looking statements included herein are made as of the date
hereof, and Synergy does not undertake any obligation to update publicly such
statements to reflect subsequent events or circumstances.


Synergy Pharmaceuticals Inc.
Gem Gokmen
Office: 212-584-7610
Mobile: 646-637-3208
Bernard Denoyer
Office: 212-297-0020
Mobile: 203-300-8147
Press spacebar to pause and continue. Press esc to stop.